Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

MYLAN-CINACALCET (30mg, 60mg & 90mg)

Canada Type I Ongoing · initiated 2025-07-16

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2025-07-15

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit

Nostrum Laboratories, Inc.

US Class II Ongoing · initiated 2025-07-11

CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that prod…

Taro-Doxorubicin Liposomal

Canada Type I Ongoing · initiated 2025-07-11

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

A.P. Deauville, LLC

US Class II Ongoing · initiated 2025-07-10

CGMP Deviations

A.P. Deauville, LLC

US Class II Ongoing · initiated 2025-07-10

CGMP Deviations

A.P. Deauville, LLC

US Class II Ongoing · initiated 2025-07-10

CGMP Deviations

Pfizer Inc.

US Class II Ongoing · initiated 2025-07-10

CGMP Deviations; particulates identified during visual inspection

Pfizer Inc.

US Class II Ongoing · initiated 2025-07-10

CGMP Deviations; particulates identified during visual inspection

Apo-Dutasteride 0.5 mg

Canada Type II Ongoing · initiated 2025-07-10

Product quality. Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health c…

Ascend Laboratories, LLC

US Class II Ongoing · initiated 2025-07-09

CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.

Ascend Laboratories, LLC

US Class II Ongoing · initiated 2025-07-09

CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.

Imprimis NJOF, LLC

US Class III Completed · initiated 2025-07-09

Sub-Potent Drug: Subpotent assay results during stability testing.

Imprimis NJOF, LLC

US Class II Completed · initiated 2025-07-09

Sub-Potent Drug: Subpotent assay results during stability testing.

Strides Pharma, Inc.

US Class II Ongoing · initiated 2025-07-09

Failed Dissolution Specifications.

Boothwyn Pharmacy LLC

US Class II Ongoing · initiated 2025-07-09

Subpotent Drug

Boothwyn Pharmacy LLC

US Class III Ongoing · initiated 2025-07-09

Subpotent Drug

Boothwyn Pharmacy LLC

US Class II Ongoing · initiated 2025-07-09

Subpotent Drug

Boothwyn Pharmacy LLC

US Class II Ongoing · initiated 2025-07-09

Subpotent Drug

NRA-AMLODIPINE 5MG

Canada Type I Ongoing · initiated 2025-07-08

Product safety. Check your medication bottle to ensure it only contains NRA-AMLODIPINE 5 mg tablets.If your bottle contains any round tablets, which are not the…

MEDLINE INDUSTRIES, LP - Northfield

US Class II Ongoing · initiated 2025-07-07

Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.

MEDLINE INDUSTRIES, LP - Northfield

US Class II Ongoing · initiated 2025-07-07

Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.

MEDLINE INDUSTRIES, LP - Northfield

US Class II Ongoing · initiated 2025-07-07

Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.

MEDLINE INDUSTRIES, LP - Northfield

US Class II Ongoing · initiated 2025-07-07

Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.

MEDLINE INDUSTRIES, LP - Northfield

US Class II Ongoing · initiated 2025-07-07

Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.